Nuformix plc (LON:NFX – Get Free Report) traded down 16.1% during trading on Wednesday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). 67,795,883 shares changed hands during trading, an increase of 635% from the average session volume of 9,222,688 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Trading Down 17.7 %
The company has a market cap of £417,848.10, a PE ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The company has a 50 day simple moving average of GBX 0.06 and a two-hundred day simple moving average of GBX 0.14.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- What Are Growth Stocks and Investing in Them
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- How to Use the MarketBeat Dividend Calculator
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
